- Home
- ALRN vs INCR Comparison
ALRN vs INCR Comparison
Compare ALRN & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRN
- INCR
- Stock Information
- Founded
- ALRN 2001
- INCR 1994
- Country
- ALRN United States
- INCR Israel
- Employees
- ALRN N/A
- INCR N/A
- Industry
- ALRN Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- ALRN Health Care
- INCR Health Care
- Exchange
- ALRN Nasdaq
- INCR Nasdaq
- Market Cap
- ALRN 76.9M
- INCR 80.1M
- IPO Year
- ALRN 2017
- INCR N/A
- Fundamental
- Price
- ALRN $3.42
- INCR $1.26
- Analyst Decision
- ALRN Strong Buy
- INCR
- Analyst Count
- ALRN 1
- INCR 0
- Target Price
- ALRN $19.00
- INCR N/A
- AVG Volume (30 Days)
- ALRN 93.8K
- INCR 36.9K
- Earning Date
- ALRN 11-26-2024
- INCR 11-26-2024
- Dividend Yield
- ALRN N/A
- INCR N/A
- EPS Growth
- ALRN N/A
- INCR N/A
- EPS
- ALRN N/A
- INCR N/A
- Revenue
- ALRN N/A
- INCR $72,420,918.00
- Revenue This Year
- ALRN N/A
- INCR N/A
- Revenue Next Year
- ALRN N/A
- INCR $39.30
- P/E Ratio
- ALRN N/A
- INCR N/A
- Revenue Growth
- ALRN N/A
- INCR N/A
- 52 Week Low
- ALRN $1.57
- INCR $1.06
- 52 Week High
- ALRN $7.42
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- ALRN 47.41
- INCR 20.78
- Support Level
- ALRN $3.37
- INCR $1.70
- Resistance Level
- ALRN $3.92
- INCR $1.78
- Average True Range (ATR)
- ALRN 0.35
- INCR 0.08
- MACD
- ALRN -0.06
- INCR -0.04
- Stochastic Oscillator
- ALRN 21.36
- INCR 5.77
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.